Please note that unlike what is written in the instructions for poster presentations, you will not be required to stand next to your poster during coffee and lunch breaks. There will be two dedicated poster presentation sessions:<\/p>\n\n\n\n
Even poster numbers<\/strong> (not abstract numbers!) will present on……. during Poster Session II <\/strong><\/p>\n\n\n\n Odd poster numbers<\/strong> will present on ……. June during Poster Session III<\/strong> <\/p>\n\n\n\n Poster print service:<\/strong><\/p>\n\n\n\n We offer a convenient local print service through Exposale for all your poster printing needs.<\/p>\n\n\n\n Pricing:<\/strong><\/p>\n\n\n\n Payment Information:<\/strong><\/p>\n\n\n\n Please note that payment must be completed before the poster is printed. You will receive a payment link from the organiser. Once payment is confirmed, your order will be processed.<\/p>\n\n\n\n Preparing Print Files for Large Format Prints:<\/strong><\/p>\n\n\n\n To ensure optimal results, please adhere to the following guidelines when preparing your print files:<\/p>\n\n\n\n Contact Information:<\/strong><\/p>\n\n\n\n To order your printed poster or for any inquiries, please contact Impreso:<\/p>\n\n\n\n Bio-engineering, stem cells and disease models <\/a> Go back<\/a><\/p>\n\n\n\n PhD. Alicia Reyes Valenzuela<\/span>P1,2<\/sup>, PhD. Mark Turner3<\/sup>, PhD. Silvia Vidal2<\/sup>, PhD. Luc Mongeau2<\/sup> Ye Jin Do<\/span>P1,2<\/sup>, Soojin Kim1<\/sup>, Jung-Hwa Oh1,2<\/sup>, Seokjoo Yoon1,2<\/sup> Sara Tirendi1,2<\/sup>, Anna Maria Bassi<\/span>P1,2<\/sup>, Mariapaola Nitti1<\/sup>, Nicole Grinovero3<\/sup>, Sonia Scarfi4,2<\/sup>, Serena Mirata4,2<\/sup>, Mario Passalacqua1,2<\/sup>, Fabrizio Loiacono5<\/sup>, Andrea Petretto3<\/sup>, Stefania Vernazza1,2<\/sup> Jean Paul Ten Klooster1<\/sup>, Kitty Van Summeren1<\/sup>, Raymond Pieters<\/span>P1<\/sup> Kitty van Summeren<\/span>P1<\/sup>, Raymond Pieters1,2<\/sup>, Jean Paul ten Klooster1<\/sup> Kathrin Laemmerhirt<\/span>P1<\/sup>, Lisa Maria Haiber1<\/sup>, Bettina Seeger1<\/sup> Shogo Nagata<\/span>P1<\/sup>, Erik Johansson1<\/sup>, Ariko Fuke1<\/sup>, Masako Kishihata1<\/sup>, Kensuke Matsumoto1<\/sup>, Arun Kumar1<\/sup>, Harry Choi1<\/sup>, Toshio Suzuki1<\/sup>, Tetsuharu Nagamoto1<\/sup>, Yuki Yamamoto1<\/sup> Malina Graf<\/span>P1<\/sup>, Frida Eriksson1<\/sup>, Paul Fitzpatrick1<\/sup> Tony Oosterveen<\/span>P1<\/sup>, Mitzy Rios de Anda1<\/sup>, Tulin Tatar Ozkan1<\/sup>, Sarah Hussain1<\/sup>, Aurora Veteleanu1<\/sup>, Stefan Milde1<\/sup>, Mariangela Iovino1<\/sup>, Dario Magnani1<\/sup>, Tom Harris-Brown1<\/sup>, Rebecca Northeast1<\/sup>, In\u00eas Ferreira1<\/sup>, Amanda Turner1<\/sup>, Will Bernard1<\/sup> Ji-Woo Kim1<\/sup>, Seongyea Jo1<\/sup>, Ji Hyeon Ryu1<\/sup>, Haneul Noh1<\/sup>, Han-Jin Park1<\/sup>, Hyemin Kim<\/span>P1<\/sup> Ji-Woo Kim Kim1<\/sup>, Seongyea Jo1<\/sup>, Ji Hyeon Ryu1<\/sup>, Haneul Noh1<\/sup>, Hyemin Kim1<\/sup>, Han-Jin Park<\/span>P1<\/sup> Isabella Ramella Gal<\/span>P1,2<\/sup>, In\u00eas Pereira Correia1,2<\/sup>, Francisca Arez1,2<\/sup>, Maria Fran\u00e7a Pereira1,2<\/sup>, In\u00eas Saldanha1,2<\/sup>, Giacomo Domenici1,2<\/sup>, Sofia Fernandes1,2<\/sup>, Catarina Freitas1,2<\/sup>, Paula Marques Alves1,2<\/sup>, Udo Maier3<\/sup>, Ana Sofia Coroadinha1,2<\/sup>, Fran\u00e7ois du Plessis3<\/sup>, Catarina Brito1,2<\/sup> Go back<\/a><\/p>\n\n\n\n Ming-Yuan Liu1<\/sup>, Jui-Feng Tsai1<\/sup>, Biing-Hui Liu<\/span>P1<\/sup> Afaf FIZAZI<\/span>P1,2<\/sup>, Clo\u00e9 SCHOELING1<\/sup>, Anne-Emilie DECLEVES2<\/sup>, Jean-Marie COLET1<\/sup>
\n\n\n\n\n
\n
\n
TOPICS<\/h2>\n\n\n\n
Cardiotoxicity and cardiac efficacy models <\/a>
Case studies for successful use and implementation of complex in vitro models <\/a>
Challenges in cosmetics safety<\/a>
Computational toxicology \u2013 in silico modelling, read-across, artificial intelligence and machine learning <\/a>
ECHA, EMA and EFSA perspectives on the use of NAMs <\/a>
Funding the development, validation and implementation of NAMs <\/a>
In vitro and in silico methods for safety assessment of medical devices <\/a>
In vitro systems to assess respiratory toxicity<\/a>
Knowledge sharing and education <\/a>
Local toxicity testing (safety and efficacy)
<\/a>Models, biomarkers and assays for developmental toxicity <\/a>
Models, biomarkers and assays for endocrine disruption <\/a>
Models, biomarkers and assays for systemic and immune toxicity <\/a>
Non-animal methods for safety testing of biopharmaceuticals\/biotherapies\/vaccines<\/a>
Organ-on-a-chip & Microphysiological Systems <\/a>
Other<\/a>
Regulatory considerations for complex NAMs <\/a>
Role of 3R centres in the dissemination and implementation of NAMs <\/a>
Serum-free approaches<\/a>
Toxicokinetics and in vitro \u2013 in vivo extrapolation<\/a><\/p>\n\n\n\nBio-engineering, stem cells and disease models <\/a><\/span><\/h2>\n\n\n\n
P1<\/a><\/h2>\n\n\n\n
Advanced lung organoids mimicking proximal and distal regions for viral infection and drug screening<\/a><\/h3>\n\n\n\n
1<\/sup> PulmonaVat
2<\/sup> McGill University
3<\/sup> Health Canada
P<\/sup> Presenting author<\/p>\n\n\n\nP2<\/a><\/h2>\n\n\n\n
Assessment of hepatic fibrosis through impedance technology using a three-dimensional cell model<\/a><\/h3>\n\n\n\n
1<\/sup> Korea Institute of Toxicology, Republic of Korea
2<\/sup> University of Science and Technology, Republic of Korea
P<\/sup> Presenting author<\/p>\n\n\n\nP3<\/a><\/h2>\n\n\n\n
Characterization of stage I retinal organoids: a proteomic approach<\/a><\/h3>\n\n\n\n
1<\/sup> Department of Experimental Medicine (DIMES), University of Genoa, Italy.
2<\/sup> Italian Center3R
3<\/sup> Core Facilities \u2013 Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, Genoa, Italy
4<\/sup> Department of Earth, Environment and Life Sciences (DISTAV), University of Genoa, Italy
5<\/sup> IRCCS Ospedale Policlinico San Martino, Genoa, Italy
P<\/sup> Presenting author<\/p>\n\n\n\nP4<\/a><\/h2>\n\n\n\n
Chicken-derived R-spondin1, Wnt3a, Nrg1 and FGF1 allow branched growth of embryonal and adult chicken intestinal organoid cultures<\/a><\/h3>\n\n\n\n
1<\/sup> University of Applied Sciences Utrecht (UASU)
P<\/sup> Presenting author<\/p>\n\n\n\nP5<\/a><\/h2>\n\n\n\n
Bridging complexity and accessibility: A simplified organoid-derived cell model for advanced in vitro applications<\/a><\/h3>\n\n\n\n
1<\/sup> Innovative Testing in Life Sciences and Chemistry (INT), University of Applied Sciences Utrecht (UASU)
2<\/sup> Institute for Risk Assessment Sciences, Population Health Sciences Division, Utrecht University, Utrecht
P<\/sup> Presenting author<\/p>\n\n\n\nP6<\/a><\/h2>\n\n\n\n
Chronic pain in a dish: modelling molecular pain mechanisms for transforming toxicity testing and drug development<\/a><\/h3>\n\n\n\n
1<\/sup> Institute for Food Quality and Food Safety, Research Group Food Toxicology and Alternative\/Complementary Methods to Animal Experiments, University of Veterinary Medicine Hannover, Foundation, 30173 Hannover, Germany
P<\/sup> Presenting author<\/p>\n\n\n\nP7<\/a><\/h2>\n\n\n\n
Reproducible generation of robust human iPSC-derived alveolar macrophage, for in vitro lung toxicology<\/a><\/h3>\n\n\n\n
1<\/sup> HiLung Inc.
P<\/sup> Presenting author<\/p>\n\n\n\nP8<\/a><\/h2>\n\n\n\n
Development of an in vitro assessment for drug-induced peripheral neuropathy using hiPSC-derived sensory neurons<\/a><\/h3>\n\n\n\n
1<\/sup> AstraZeneca, R&D BioPharmaceuticals, Clinical Pharmacology & Safety Sciences
P<\/sup> Presenting author<\/p>\n\n\n\nP9<\/a><\/h2>\n\n\n\n
Scalable and well-defined human CNS co-culture platforms suitable for modelling excitatory-inhibitory neuron imbalances in drug discovery and safety studies<\/a><\/h3>\n\n\n\n
1<\/sup> bit.bio
P<\/sup> Presenting author<\/p>\n\n\n\nP10<\/a><\/h2>\n\n\n\n
Comparative study of CYP450 gene regulation in human pluripotent stem cell-derived liver 2D cell and 3D organoid models<\/a><\/h3>\n\n\n\n
1<\/sup> Korea Institute of Toxicology
P<\/sup> Presenting author<\/p>\n\n\n\nP11<\/a><\/h2>\n\n\n\n
Application of scalable hiPSC-derived liver organoids for chemical hazard screening<\/a><\/h3>\n\n\n\n
1<\/sup> Korea Institute of Toxicology
P<\/sup> Presenting author<\/p>\n\n\n\nP12<\/a><\/h2>\n\n\n\n
Engineering a human hiPSC-derived 3D liver model to predict early innate immune toxicity to AAV gene therapy<\/a><\/h3>\n\n\n\n
1<\/sup> iBET – Institute of Experimental Biology and Technology
2<\/sup> Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier, Universidade Nova de Lisboa
3<\/sup> Boehringer Ingelheim Pharma GmbH & Co. KG
P<\/sup> Presenting author<\/p>\n\n\n\nCardiotoxicity and cardiac efficacy models<\/a><\/span><\/h2>\n\n\n\n
P13<\/a><\/h2>\n\n\n\n
Beauvericin-induced cardiotoxicity in H9C2 cardiomyocytes and zebrafish embryos<\/a><\/h3>\n\n\n\n
1<\/sup> Graduate Institute of Toxicology, National Taiwan University
P<\/sup> Presenting author<\/p>\n\n\n\nP14<\/a><\/h2>\n\n\n\n
Could succination lead to cardiotoxcity<\/a><\/h3>\n\n\n\n
1<\/sup> Human biology and toxicology laboratory. University of Mons. Belgium
2<\/sup> Metabolic and Molecular Biochemistry Laboratory. University of Mons. Belgium
P<\/sup> Presenting author<\/p>\n\n\n\n